Skip to main content
. 2017 Apr 20;12:67. doi: 10.1186/s13014-017-0791-2

Table 1.

Patient demographics, disease and treatment characteristics

Characteristic n = 43 V20Gy to bSVZ ≤84% (n = 32) V20Gy to bSVZ >84% (n = 8) p
Age at surgery (years) (median, range) 59 (25–85) 60 (30–85) 64.5 (45–76) 0.710
Gender 0.222
 Male 28 (65.1%) 19 (59.4%) 7 (87.5%)
 Female 15 (34.9%) 13 (40.6%) 1 (12.5%)
ECOG performance status at diagnosis 0.080
 0–1 33 (76.7%) 28 (87.5%) 3 (37.5%)
 2–4 10 (23.3%) 4 (12.5%) 5 (62.5%)
Tumor side 0.406
 Right 29 (67.4%) 22 (68.8%) 7 (87.5%)
 Left 13 (30.2%) 10 (31.3%) 1 (12.5%)
 Both 1 (2.4%) 0 0
Tumor location 0.014
 Frontal 12 (27.9%) 5 (15.6%) 6 (75%)
 Temporal 18 (41.9%) 16 (50%) 1 (12.5%)
 Parietal 10 (23.3%) 9 (28.1%) 1 (12.5%)
 Occipital 2 (4.7%) 2 (6.3%) 0
 Thalamic 1 (2.3%) 0 0
Multilobar lesion 0.689
 No 29 (67.4%) 20 (62.5%) 6 (75%)
 Yes 14 (32.6%) 12 (37.5%) 2 (25%)
Tumor SVZ contact 0.424
 Yes 26 (63.4%) 21 (67.7%) 4 (50%)
 No 15 (36.6%) 10 (32.3%) 4 (50%)
 Missing 2 1 0
Minimal distance to SVZ (mm) 0.366
 Median (range) 0 (0–27.8) 0 (0–27.8) 5.3 (0–24.6)
 Missing 2 1 0
T1 post-gadolinium volume (cm3) 0.585
 Median (range) 40.8 (4.4–151.9) 40.5 (4.4–94.5) 46.6 (6.5–151.9)
 Missing 3 1
FLAIR volume (cm3) 0.290
 Median (range) 151.4 (24.8–342.6) 115.3 (24.8–269) 194.1 (69.8–342.6)
MGMT status 0.413
 Methylated 14 (35%) 9 (31%) 4 (50%)
 Unmethylated 26 (65%) 20 (69%) 4 (50%)
 Unknown 3 3 0
Extent of resection 0.430
 GTR/NTR 19 (44.2%) 13 (40.6%) 5 (62.5%)
 STR 24 (55.8%) 19 (59.4%) 3 (37.5%)
Number of cycles of adjuvant temozolomide (median, range) 6 (1–15) 3 (1–15) 5 (2–9) 0.510

Abbreviations: MGMT O6-methylguanine-DNA-methyltransferase, GTR Gross Total Resection, NTR Near Total Resection, STR SubTotal Resection, bSVZ bilateral SVZ, VxGy volume of SVZ (%) receiving more than x Gy